Hughes David J, Kostrzewski Tomasz, Sceats Emma L
CN Bio Innovations Limited, Welwyn Garden City AL73AX, UK.
Exp Biol Med (Maywood). 2017 Oct;242(16):1593-1604. doi: 10.1177/1535370217708976. Epub 2017 May 15.
Liver disease represents a growing global health burden. The development of in vitro liver models which allow the study of disease and the prediction of metabolism and drug-induced liver injury in humans remains a challenge. The maintenance of functional primary hepatocytes cultures, the parenchymal cell of the liver, has historically been difficult with dedifferentiation and the consequent loss of hepatic function limiting utility. The desire for longer term functional liver cultures sparked the development of numerous systems, including collagen sandwiches, spheroids, micropatterned co-cultures and liver microphysiological systems. This review will focus on liver microphysiological systems, often referred to as liver-on-a-chip, and broaden to include platforms with interconnected microphysiological systems or multi-organ-chips. The interconnection of microphysiological systems presents the opportunity to explore system level effects, investigate organ cross talk, and address questions which were previously the preserve of animal experimentation. As a field, microphysiological systems have reached a level of maturity suitable for commercialization and consequent evaluation by a wider community of users, in academia and the pharmaceutical industry. Here scientific, operational, and organizational considerations relevant to the wider adoption of microphysiological systems will be discussed. Applications in which microphysiological systems might offer unique scientific insights or enable studies currently feasible only with animal models are described, and challenges which might be addressed to enable wider adoption of the technologies are highlighted. A path forward which envisions the development of microphysiological systems in partnerships between academia, vendors and industry, is proposed. Impact statement Microphysiological systems are in vitro models of human tissues and organs. These systems have advanced rapidly in recent years and are now being commercialized. To achieve wide adoption in the biological and pharmaceutical research communities, microphysiological systems must provide unique insights which translate to humans. This will be achieved by identifying key applications and making microphysiological systems intuitive to use.
肝脏疾病是一个日益严重的全球健康负担。开发能够研究疾病以及预测人体新陈代谢和药物性肝损伤的体外肝脏模型仍然是一项挑战。维持功能性原代肝细胞培养物(肝脏的实质细胞)一直以来都很困难,因为去分化以及随之而来的肝功能丧失限制了其实用性。对长期功能性肝脏培养物的需求促使了众多系统的开发,包括胶原三明治培养法、球体培养法、微图案共培养法和肝脏微生理系统。本综述将聚焦于肝脏微生理系统(通常称为芯片上的肝脏),并扩展到包括具有相互连接的微生理系统或多器官芯片的平台。微生理系统的相互连接为探索系统水平效应、研究器官间相互作用以及解决以前属于动物实验范畴的问题提供了机会。作为一个领域,微生理系统已经达到了适合商业化并由学术界和制药行业更广泛用户群体进行评估的成熟水平。这里将讨论与更广泛采用微生理系统相关的科学、操作和组织方面的考虑因素。描述了微生理系统可能提供独特科学见解或使目前仅用动物模型才能进行的研究成为可能的应用,并强调了为使这些技术得到更广泛采用可能需要解决的挑战。提出了一条设想在学术界、供应商和行业之间建立伙伴关系来开发微生理系统的前进道路。影响声明微生理系统是人体组织和器官的体外模型。这些系统近年来发展迅速,目前正在商业化。为了在生物学和制药研究领域得到广泛应用,微生理系统必须提供可转化为人体情况的独特见解。这将通过确定关键应用并使微生理系统易于使用来实现。